Breaking News Instant updates and real-time market news.

TBPH

Theravance Biopharma

$32.40

-0.57 (-1.73%)

08:32
02/17/17
02/17
08:32
02/17/17
08:32

Theravance Biopharma reports 'positive' data on TD-1473 at ECCO

Theravance Biopharma announced the presentation of positive clinical data for TD-1473, a novel, potent, and orally administered pan-Janus kinase inhibitor designed to be intestinally restricted, at the 12th Congress of the European Crohn's and Colitis Organization. In a poster presentation, the Company reported further data from its completed Phase 1 study of single-ascending and multiple-ascending doses of TD-1473. Results of the study were first announced in June 2016. Theravance Biopharma is developing TD-1473 as an investigational compound with the potential to treat a range of inflammatory intestinal diseases and is currently conducting a Phase 1b study of the compound in patients with moderate to severe ulcerative colitis. The findings presented at ECCO reaffirm previously announced results from the Phase 1 study which demonstrated TD-1473 to be generally well tolerated as a single dose (up to 1000 mg) and as a daily dose (up to 300 mg) given for 14 days. Newly presented data demonstrated that no moderate, severe or serious treatment emergent adverse events were reported in subjects dosed with TD-1473, and no TEAEs of any severity led to study discontinuation. TEAEs were higher in subjects receiving placebo than in subjects receiving TD-1473 in both the single-ascending and multiple-ascending dose portions of the study. Additionally, the study data presented demonstrated that TD-1473 exhibited a pharmacokinetic profile consistent with the Company's goal of designing the compound to penetrate the intestinal wall from within and act directly at the site of inflammation with minimal systemic exposure. Across a range of doses, the observed systemic concentrations of TD-1473 were consistent with low bioavailability and intestinal restriction. For all doses in both the single-ascending and multiple-ascending groups, the amount of TD-1473 that was excreted in the urine was less than 0.5% of the administered dose. TD-1473 is designed to be intestinally restricted, which potentially represents a key competitive advantage for the compound based on the range of safety and tolerability concerns associated with systemically available JAK inhibitors.

  • 23

    Feb

  • 27

    Feb

TBPH Theravance Biopharma
$32.40

-0.57 (-1.73%)

11/03/16
PIPR
11/03/16
INITIATION
Target $42
PIPR
Overweight
Theravance Biopharma initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Joshua Schimmer initiated Theravance Biopharma with an Overweight and a $42 price target saying its medicinal chemistry expertise in developing topical therapies against validated targets is an underappreciated long-term value driver.
12/21/16
PIPR
12/21/16
NO CHANGE
PIPR
Piper lays out top BioPharma picks for 2017
Piper Jaffray analysts laid out their top BioPharma picks for 2017. Analyst Richard Purkiss favors Pfizer (PFE) and Eli Lilly (LLY) as his top large pharma picks. Analyst Joshua Schimmer calls Gilead (GILD) and Alexion (ALXN) his top large cap picks. Analyst David Amsellem names Horizon Pharma (HZNP) his top specialty pharma pick. Piper's other top Biopharma picks for 2017 include ACADIA (ACAD), Aimmune (AIMT), Akorn (AKRX), Alnylam (ALNY), Axovant Sciences (AXON), Cara Therapeutics (CARA), CoLucid Pharmaceuticals (CLCD), Eale Pharmaceuticals (EGRX), Exelixis (EXEL), Ionis Pharmaceuticals (IONS), Mallinckrodt (MNK), Neurocrine (NBIX), Nektar (NKTR), Otonomy (OTIC), Reata Pharmaceuticals (RETA), Rigel Pharmaceuticals (RIGL), Ignyta (RXDX), Theravance Biopharma (TBPH), Versartis (VSAR) and Voyager Therapeutics (VYGR). The analysts look for recent momentum in BioPharma to continue in 2017. They believe innovation and potentially repatriation should lead to increased merger activity.
12/21/16
NEED
12/21/16
INITIATION
Target $40
NEED
Buy
Theravance Biopharma initiated with a Buy at Needham
Needham analyst Alan Carr initiated Theravance Biopharma with a Buy and a $40 price target saying it has a diversified strategy and pipeline, with a mix of internal and out-licensed programs across various indications, derived from a small molecule drug discovery platform.
01/27/17
EAMC
01/27/17
INITIATION
Target $16
EAMC
Sell
Theravance Biopharma initiated with a Sell at Empire
Empire started Theravance Biopharma with a Sell rating and $16 price target. Trial results for several products in development are expected during 2017, but the firm notes these are early development products or products that it believes will address limited or highly competitive markets.

TODAY'S FREE FLY STORIES

OIS

Oil States

$24.68

1.275 (5.45%)

11:52
12/13/17
12/13
11:52
12/13/17
11:52
Recommendations
Oil States analyst commentary  »

Oil States target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

BURL

Burlington Stores

$110.92

1.3 (1.19%)

11:50
12/13/17
12/13
11:50
12/13/17
11:50
Options
Burlington draws a bullish option play as shares see strength »

Burlington draws a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BT

BT Group

$18.04

-0.0501 (-0.28%)

11:49
12/13/17
12/13
11:49
12/13/17
11:49
Upgrade
BT Group rating change  »

BT Group upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UHT

Universal Health Realty

$75.28

1.705 (2.32%)

11:45
12/13/17
12/13
11:45
12/13/17
11:45
Conference/Events
Universal Health Realty management to meet with Jefferies »

Group luncheon to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

11:40
12/13/17
12/13
11:40
12/13/17
11:40
General news
Bund/T-note spread widening remains intact »

Bund/T-note spread…

CERN

Cerner

$70.36

0.23 (0.33%)

11:39
12/13/17
12/13
11:39
12/13/17
11:39
Periodicals
VA Secretary says contract with Cerner held up by questions, Politico reports »

Veterans Affairs…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CACC

Credit Acceptance

$326.25

3.97 (1.23%)

11:34
12/13/17
12/13
11:34
12/13/17
11:34
Hot Stocks
PlainSite says Credit Acceptance disclosures belie 'deeply flawed' model »

In a "Reality…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSGP

CoStar Group

$287.83

-2.67 (-0.92%)

11:33
12/13/17
12/13
11:33
12/13/17
11:33
Conference/Events
CoStar Group management to meet with Needham »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

  • 15

    Dec

  • 26

    Feb

ROG

Rogers Corporation

$158.59

1.4 (0.89%)

11:30
12/13/17
12/13
11:30
12/13/17
11:30
Conference/Events
Rogers Corporation management to meet with Needham »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 15

    Dec

11:30
12/13/17
12/13
11:30
12/13/17
11:30
General news
FX Action: USD-CAD »

FX Action: USD-CAD has…

ROG

Rogers Corporation

$158.89

1.7 (1.08%)

11:29
12/13/17
12/13
11:29
12/13/17
11:29
Conference/Events
Rogers Corporation management to meet with B. Riley FBR »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 15

    Dec

HDP

Hortonworks

$19.76

0.18 (0.92%)

11:25
12/13/17
12/13
11:25
12/13/17
11:25
Conference/Events
Hortonworks management to meet with Needham »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 14

    Dec

  • 26

    Feb

CACC

Credit Acceptance

$326.25

3.97 (1.23%)

11:20
12/13/17
12/13
11:20
12/13/17
11:20
Hot Stocks
Credit Acceptance moves lower following short report from PlainSite »

Shares of Credit…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

11:17
12/13/17
12/13
11:17
12/13/17
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

11:16
12/13/17
12/13
11:16
12/13/17
11:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RL

Ralph Lauren

$96.15

-3.99 (-3.98%)

11:13
12/13/17
12/13
11:13
12/13/17
11:13
Hot Stocks
Ralph Lauren falls after Bofa/Merrill downgrade cites 'dimming' margin story »

Shares of Ralph Lauren…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TGT

Target

$61.58

0.555 (0.91%)

11:10
12/13/17
12/13
11:10
12/13/17
11:10
Hot Stocks
Target: Shipt to continue to run business independently post-acquisition »

Shipt will be a wholly…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TMUS

T-Mobile

$63.48

0.41 (0.65%)

, T

AT&T

$37.75

-0.35 (-0.92%)

11:10
12/13/17
12/13
11:10
12/13/17
11:10
Hot Stocks
Cable, telecom stocks dip as T-Mobile plans to bring 'un-carrier' to TV »

T-Mobile (TMUS) is…

TMUS

T-Mobile

$63.48

0.41 (0.65%)

T

AT&T

$37.75

-0.35 (-0.92%)

ROKU

Roku

$46.95

-1.03 (-2.15%)

CMCSA

Comcast

$39.51

1.07 (2.78%)

CMCSK

Comcast

CHTR

Charter

$329.99

-1.5 (-0.45%)

VZ

Verizon

$52.82

-0.375 (-0.71%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 13

    Dec

  • 13

    Dec

LITE

Lumentum

$51.75

-1.75 (-3.27%)

, FNSR

Finisar

$19.30

-0.51 (-2.57%)

11:09
12/13/17
12/13
11:09
12/13/17
11:09
Recommendations
Lumentum, Finisar, Apple analyst commentary  »

Apple's investment…

LITE

Lumentum

$51.75

-1.75 (-3.27%)

FNSR

Finisar

$19.30

-0.51 (-2.57%)

AAPL

Apple

$171.70

-0.97 (-0.56%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NFLX

Netflix

$185.73

-0.49 (-0.26%)

11:09
12/13/17
12/13
11:09
12/13/17
11:09
Periodicals
Netflix executive fired over Masterson assault comments, Page Six says »

Netflix director of kids…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TGT

Target

$61.64

0.62 (1.02%)

11:06
12/13/17
12/13
11:06
12/13/17
11:06
Technical Analysis
Technical View: Target spikes after acquiring Shipt for $550M »

The stock was last up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TGT

Target

$61.70

0.68 (1.11%)

11:02
12/13/17
12/13
11:02
12/13/17
11:02
Hot Stocks
Breaking Hot Stocks news story on Target »

Target to bring same-day…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TGT

Target

$61.69

0.67 (1.10%)

11:01
12/13/17
12/13
11:01
12/13/17
11:01
Hot Stocks
Breaking Hot Stocks news story on Target »

Target: Same-day delivery…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TGT

Target

$61.72

0.71 (1.16%)

11:01
12/13/17
12/13
11:01
12/13/17
11:01
Hot Stocks
Target to buy same-day delivery platform Shipt for $550M in cash »

Target announced it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AYI

Acuity Brands

$165.44

-8.79 (-5.05%)

10:59
12/13/17
12/13
10:59
12/13/17
10:59
Technical Analysis
Technical View: Acuity Brands tumbles, levels to watch »

The shares were last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jan

  • 09

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.